OROlivier Reelfs

Olivier Reelfs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Olivier Reelfs has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Antony Richard Young

    King’s College London, London, UK

    2 shared publications
  • Peter Karran

    Cancer Research UK London Research Institute, Clare Hall Laboratories, South Mimms, Herts, U.K.

    2 shared publications
  • Peter Macpherson

    King's College London, School of Medicine, Division of Genetics and Molecular Medicine, St John's Institute of Dermatology, London, SE1 9RT, Cancer Research UK London Research Institute, Clare Hall Laboratories, South Mimms, Herts EN6 3LD and Department of Chemistry and Analytical Sciences, The Open University, Walton Hall, Milton Keynes MK7 6AA, UK

    1 shared publication
  • Xiaolin Ren

    King's College London, School of Medicine, Division of Genetics and Molecular Medicine, St John's Institute of Dermatology, London, SE1 9RT, Cancer Research UK London Research Institute, Clare Hall Laboratories, South Mimms, Herts EN6 3LD and Department of Chemistry and Analytical Sciences, The Open University, Walton Hall, Milton Keynes MK7 6AA, UK

    1 shared publication
  • Yao-Zhong Xu

    School of Life, Health and Chemical Sciences, The Open University, Milton Keynes MK7 6AA, U.K.

    1 shared publication

Latest Publications

  • 4-thiothymidine sensitization of DNA to UVA offers potential for a novel photochemotherapy

    by Olivier Reelfs, Peter Karran, Antony R. Young

    Photochemotherapy, in which ultraviolet radiation (UVR: 280–400 nm) or visible light is combined with a photosensitizing drug to produce a therapeutic effect that neither drug or radiation can achieve alone, is a proven therapeutic strategy for a number of non-malignant hyperproliferative skin conditions and various cancers. Examples are psoralen plus UVA (320–400 nm) radiation (PUVA) and photodynamic therapy (PDT). All existing photochemotherapies have drawbacks – for example the association of PUVA with the development of skin cancer, and pain that is often associated with PDT treatment of skin lesions. There is a clear need to develop alternative approaches that involve lower radiation doses and/or improved selectivity for target cells. In this review, we explore the possibility to address this need by exploiting thionucleoside-mediated DNA photosensitisation to low, non toxic doses of UVA radiation.


  • Open Access

    Identification of potentially cytotoxic lesions induced by UVA photoactivation of DNA 4-thiothymidine in human cells

    by Olivier Reelfs, Peter Macpherson, Xiaolin Ren, Yao-Zhong Xu, Peter Karran, Antony R. Young

    Photochemotherapy—in which a photosensitizing drug is combined with ultraviolet or visible radiation—has proven therapeutic effectiveness. Existing approaches have drawbacks, however, and there is a clinical need to develop alternatives offering improved target cell selectivity. DNA substitution by 4-thiothymidine (S 4 TdR) sensitizes cells to killing by ultraviolet A (UVA) radiation. Here, we demonstrate that UVA photoactivation of DNA S 4 TdR does not generate reactive oxygen or cause direct DNA breakage and is only minimally mutagenic. In an organotypic human skin model, UVA penetration is sufficiently robust to kill S 4 TdR-photosensitized epidermal cells. We have investigated the DNA lesions responsible for toxicity. Although thymidine is the predominant UVA photoproduct of S 4 TdR in dilute solution, more complex lesions are formed when S 4 TdR-containing oligonucleotides are irradiated. One of these, a thietane/S 5 -(6-4)T:T, is structurally related to the (6-4) pyrimidine:pyrimidone [(6-4) Py:Py] photoproducts induced by UVB/C radiation. These lesions are detectable in DNA from S 4 TdR/UVA-treated cells and are excised from DNA more efficiently by keratinocytes than by leukaemia cells. UVA irradiation also induces DNA interstrand crosslinking of S 4 TdR-containing duplex oligonucleotides. Cells defective in repairing (6-4) Py:Py DNA adducts or processing DNA crosslinks are extremely sensitive to S 4 TdR/UVA indicating that these lesions contribute significantly to S 4 TdR/UVA cytotoxicity.